BRPI0610322B8 - inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica - Google Patents

inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica

Info

Publication number
BRPI0610322B8
BRPI0610322B8 BRPI0610322A BRPI0610322A BRPI0610322B8 BR PI0610322 B8 BRPI0610322 B8 BR PI0610322B8 BR PI0610322 A BRPI0610322 A BR PI0610322A BR PI0610322 A BRPI0610322 A BR PI0610322A BR PI0610322 B8 BRPI0610322 B8 BR PI0610322B8
Authority
BR
Brazil
Prior art keywords
receptor signaling
hgf
pharmaceutical composition
receptor
signaling inhibitors
Prior art date
Application number
BRPI0610322A
Other languages
English (en)
Portuguese (pt)
Inventor
Wahhab Amal
Vaisburg Arkadii
Raeppel Franck
Gaudette Frederic
Zhan Lijie
Isakovic Ljubomir
Granger Marie-Claude
Mannion Michael
Zhou Nancy
Bernstein Naomy
Mario Saavedra Oscar
Deziel Robert
Raeppel Stephane
William Claridge Stephen
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of BRPI0610322A2 publication Critical patent/BRPI0610322A2/pt
Publication of BRPI0610322B1 publication Critical patent/BRPI0610322B1/pt
Publication of BRPI0610322B8 publication Critical patent/BRPI0610322B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0610322A 2005-05-20 2006-05-19 inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica BRPI0610322B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68303605P 2005-05-20 2005-05-20
US60/683,036 2005-05-20
US75490205P 2005-12-29 2005-12-29
US60/754,902 2005-12-29
US78505406P 2006-03-22 2006-03-22
US60/785,054 2006-03-22
PCT/IB2006/004306 WO2008041053A2 (en) 2005-05-20 2006-05-19 Inhibitors of vegf receptor and hgf receptor signaling

Publications (3)

Publication Number Publication Date
BRPI0610322A2 BRPI0610322A2 (pt) 2010-06-15
BRPI0610322B1 BRPI0610322B1 (pt) 2020-12-01
BRPI0610322B8 true BRPI0610322B8 (pt) 2021-05-25

Family

ID=39190471

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610322A BRPI0610322B8 (pt) 2005-05-20 2006-05-19 inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica

Country Status (13)

Country Link
US (2) US8093264B2 (enExample)
EP (1) EP1957498B1 (enExample)
JP (1) JP5148499B2 (enExample)
KR (1) KR101378716B1 (enExample)
CN (1) CN101796055B (enExample)
AU (1) AU2006343808B2 (enExample)
BR (1) BRPI0610322B8 (enExample)
CA (1) CA2611370C (enExample)
ES (1) ES2623221T3 (enExample)
IL (1) IL187484A (enExample)
MX (1) MX2007014616A (enExample)
NZ (1) NZ564283A (enExample)
WO (1) WO2008041053A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
EP1781664B1 (en) * 2004-07-30 2013-09-04 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
MX2007014617A (es) * 2005-05-20 2008-02-11 Methylgene Inc Inhibidores de senalizacion de receptor de factor de crecimiento endotelial bascular y receptor de factor de crecimiento de hepatocitos.
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
US8003662B2 (en) * 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
US7723330B2 (en) 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
CA2651898A1 (en) 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2009026701A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
CA2716348C (en) 2008-02-21 2017-04-04 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome p450
MX2010009729A (es) * 2008-03-05 2010-12-21 Methylgene Inc Inhibidores de actividad de proteina tirosina quinasa.
BRPI0918971A2 (pt) 2008-08-26 2015-12-01 Boehringer Ingelheim Int tienopirimidinas para composições farmacêuticas
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
CA2742007C (en) * 2008-10-29 2014-07-08 Deciphera Pharmaceuticals, Llc Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
KR20120124428A (ko) * 2009-12-30 2012-11-13 아르퀼 인코포레이티드 치환된 피롤로-아미노피리미딘 화합물
ES2562959T3 (es) 2010-02-26 2016-03-09 Evotec International Gmbh Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
MX2012009735A (es) 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
CN101863911A (zh) * 2010-04-13 2010-10-20 艾琪康医药科技（上海）有限公司 一种1-r1-3,4-脱氢-3或4-r6-哌啶的制备方法
MX2012012031A (es) 2010-04-16 2012-12-17 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
EP2594566A4 (en) 2010-07-16 2014-10-01 Kyowa Hakko Kirin Co Ltd AROMATIC HETEROCYCLIC NITROGEN CYCLE DERIVATIVE
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
MX352844B (es) 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
US9925193B2 (en) 2012-11-20 2018-03-27 Proqinase Gmbh Thioether derivatives as protein kinase inhibitors
SG11201607990QA (en) 2014-04-25 2016-11-29 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
CN105348213A (zh) * 2015-09-22 2016-02-24 武汉理工大学 β-氟烷基-β-氨基酸类化合物的制备方法
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
AU2017315343A1 (en) 2016-08-24 2019-02-28 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
CN110423218A (zh) * 2019-08-09 2019-11-08 新乡双鹭药业有限公司 一种苹果酸卡博替尼合成中杂质的制备方法
CN113336768B (zh) 2020-02-18 2022-08-19 深圳海王医药科技研究院有限公司 一种多靶点酪氨酸激酶抑制剂
CN114957136A (zh) * 2021-02-24 2022-08-30 南京科默生物医药有限公司 一种用作vegfr抑制剂的抗肿瘤化合物及其用途
CN115215803B (zh) * 2022-09-19 2022-12-30 苏州美诺医药科技有限公司 一种4-卤代-1-(二氟甲基)-1h-咪唑的制备方法
CN117902987A (zh) * 2024-01-22 2024-04-19 安庆双启医药科技有限公司 一种3-氟-5-碘苯胺的制备方法
WO2025239980A1 (en) * 2024-05-13 2025-11-20 University Of Virginia Patent Foundation Compounds for the inhibition of kifc3, methods of making the same, and pharmaceutical compositions comprising the same
US20260116871A1 (en) * 2024-10-24 2026-04-30 Fujian Haixi Pharmaceuticals Co., Ltd. Tyrosine Kinase Inhibitors and Uses Thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69417918T2 (de) 1993-11-30 2000-01-05 Mcgill University, Montreal Dna methyltransferase inhibierung
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6268137B1 (en) * 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
WO1998054313A2 (en) * 1997-05-30 1998-12-03 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6020318A (en) 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides
SK6652000A3 (en) * 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6066625A (en) 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU4231299A (en) 1998-06-04 1999-12-20 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
US6953783B1 (en) * 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
KR20020007398A (ko) 1999-05-03 2002-01-26 추후제출 히스톤 탈아세틸화효소의 억제
HK1045306A1 (zh) 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
KR20100035666A (ko) 1999-11-23 2010-04-05 메틸진 인크. 히스톤 디아세틸라제의 억제제
JP2003528074A (ja) 2000-03-24 2003-09-24 メチルジーン インコーポレイテッド ヒストン脱アセチル化酵素の阻害剤
EP2093292A2 (en) 2000-03-24 2009-08-26 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
BR0111377A (pt) 2000-06-06 2003-06-03 Pfizer Prod Inc Derivados de tiofeno úteis como agentes anticancerìgenos
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
CA2454538A1 (en) * 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
CA2465978C (en) 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
MXPA04008403A (es) 2002-03-01 2004-11-26 Pfizer Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso.
EP1551795A1 (en) 2002-10-17 2005-07-13 Methylgene, Inc. Inhibitors of histone deacetylase
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
WO2005021554A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7581674B2 (en) * 2003-11-21 2009-09-01 Charles Cohen Financial transaction system and method
US7626030B2 (en) * 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) * 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
DE602005024274D1 (de) 2004-07-16 2010-12-02 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
EP1781664B1 (en) * 2004-07-30 2013-09-04 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
US7647492B2 (en) 2004-09-15 2010-01-12 Check Point Software Technologies Inc. Architecture for routing and IPSec integration
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
AU2006229343A1 (en) 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
CN101374801B (zh) * 2005-12-19 2014-07-02 梅特希尔基因公司 用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂
US8003662B2 (en) 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
WO2007107005A1 (en) 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
BRPI0610322A2 (pt) 2010-06-15
JP5148499B2 (ja) 2013-02-20
KR20080059112A (ko) 2008-06-26
US8093264B2 (en) 2012-01-10
CN101796055A (zh) 2010-08-04
US8329726B2 (en) 2012-12-11
IL187484A0 (en) 2011-08-01
AU2006343808A1 (en) 2008-04-10
AU2006343808B2 (en) 2012-03-29
EP1957498B1 (en) 2017-02-15
IL187484A (en) 2014-04-30
CA2611370C (en) 2014-11-25
WO2008041053A3 (en) 2009-12-23
MX2007014616A (es) 2009-08-12
US20120083482A1 (en) 2012-04-05
BRPI0610322B1 (pt) 2020-12-01
EP1957498A2 (en) 2008-08-20
ES2623221T3 (es) 2017-07-10
NZ564283A (en) 2011-07-29
KR101378716B1 (ko) 2014-04-10
WO2008041053A2 (en) 2008-04-10
CN101796055B (zh) 2013-09-04
EP1957498A4 (en) 2010-10-27
US20070004675A1 (en) 2007-01-04
CA2611370A1 (en) 2006-11-20
JP2009504804A (ja) 2009-02-05

Similar Documents

Publication Publication Date Title
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
BRPI0513982A (pt) inibidores de sinalização de receptor de vegf e receptor de hgf
TN2009000255A1 (en) Quinazolines for pdk1 inhibition
BR112013011441A2 (pt) composto, composição farmacêutica, e, uso de um composto
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
BRPI0710521A2 (pt) quinazolinas para inibição de pdk1
ECSP088804A (es) Antagonistas de los piridil amida de los canales de calcio de tipo t
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0615097A2 (pt) agentes para previnir e tratar distúrbios que envolvem modulação dos receptores de ryr
ECSP10010035A (es) Amidas heterocíclicas y sus métodos de uso
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
CL2008003339A1 (es) Compuestos derivados de pirimidin-2(1h)-ona, inhibidores de la 11b-hidroxiesteroide deshidrogenasa 1; composicion farmaceutica, util para el tratamiento de enfermedades tales como obesidad, hipertension e hiperlipidemia.
BR112013004368A2 (pt) compostos tendo a fórmula geral (i) e composição farmacêutica
DOP2012000006A (es) Agonista de gpr119
CL2007003758A1 (es) Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer.
WO2007054831A3 (en) Inhibitors of vegf receptor and hgf receptor signaling
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: APRESENTE O DEPOSITANTE COPIA DA FOLHA DE ROSTO DA PUBLICACAO INTERNACIONAL DO PEDIDO, CONFORME O DISPOSTO NO ITEM 9.3 DO AN NO 128/1997.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF